Genprex Faces Nasdaq Delisting for Sub-$1 Price, Ineligible for Compliance Period
GNPX is trading near its 52-week low of $0.624 (3.4% above the low) on light trading volume (0.3× avg).
Summary
Genprex received a formal delisting notice from Nasdaq for failing to maintain the $1.00 minimum bid price. Critically, the company is ineligible for a compliance period due to a recent 1:50 reverse stock split in October 2025. This follows an 8-K filed today and previous proxy statements in April where the company sought approval for yet another reverse split to avoid this exact scenario. Delisting would severely impact the stock's liquidity and investor confidence, moving it to less regulated OTC markets. The company plans to request a hearing, which will temporarily stay the delisting, and may pursue another reverse split.
At the time of this announcement, GNPX was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.62 to $55.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.